Adding a New Drug to Standard Chemotherapy for Returning Brain Tumors

Plain-English translation of NCT05432804 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing whether , a newer anti-cancer medication, works better when combined with (the standard chemotherapy for brain tumors) compared to alone. You would be in one of two groups: one receiving only the standard chemotherapy, and the other receiving standard chemotherapy plus the new medication. The goal is to see if this combination helps people whose glioblastoma has come back after their initial treatment.

Glioblastoma is an aggressive brain cancer, and many patients experience their tumor returning even after initial treatment. Doctors are looking for ways to improve outcomes for these patients, and this medication may help slow or stop the cancer's return.

Do you qualify?

You likely qualify if…

you have been diagnosed with glioblastoma that has returned after initial treatment and have had surgery or a biopsy to confirm the recurrence
you previously received standard chemotherapy and radiation therapy for your initial brain tumor diagnosis
you are at least 18 years old
you have adequate organ function (normal blood counts, liver, and kidney function) as shown by recent lab work
you are in good enough health to handle cancer treatment (Karnofsky performance status of 60% or higher)

You likely don't qualify if…

you are pregnant, breastfeeding, or unwilling to use reliable birth control, since this medication may harm a developing baby
you have untreated or uncontrolled heart disease, or a history of serious heart problems
you have active, untreated infections including HIV, hepatitis B, or hepatitis C (though controlled infections may be okay)
you have already received other treatments for your recurrent tumor besides surgery or biopsy

What participation looks like

You will receive treatment in 28-day cycles. One group takes the standard chemotherapy by mouth on days 1–5 of each cycle plus a placebo on days 8 and 15. The other group takes standard chemotherapy on days 1–5 plus the new medication on days 8 and 15. Throughout your time on the trial, you will have regular MRI scans to check how your tumor is responding and blood tests to monitor your health. After you finish treatment, you will have follow-up visits every 2 months for up to 2 years.

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Adding a New Drug to Standard Chemotherapy for Returning Brain Tumors

What is this trial?

Do you qualify?

What participation looks like

Trial locations(36 sites)